Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease
Status unconfirmed
Conditions studied: Inflammatory Bowel Diseases
In brief
The aim of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.
Key facts
- Study ID
- NCT05014555
- Run by
- GI Alliance
- People needed
- 400
- Starts
- 2023-07-05
- Expected to finish
- 2024-01-01
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Jacksonville, FL — Jacksonville, Florida, United States
- GI Alliance — Baton Rouge, Louisiana, United States
- GI Alliance — Southlake, Texas, United States
- University of Wisconsin — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.